{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:35:31Z","timestamp":1790030131656,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"DOI":"10.1093\/cid\/cit112","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T20:34:54Z","timestamp":1362170094000},"page":"1562-1569","source":"Crossref","is-referenced-by-count":160,"title":["Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg\/L: A Matched Cohort Study"],"prefix":"10.1093","volume":"56","author":[{"given":"Kyle P.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravina","family":"Kullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lephart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"key\n\t\t\t\t20170623052554_CIT112C1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/499367","article-title":"Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992\u20132003","volume":"42","author":"Klevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C2","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.00582-08","article-title":"Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)","volume":"46","author":"Rybak","year":"2008","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623052554_CIT112C3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijantimicag.2010.10.029","article-title":"Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004\u20132009","volume":"37","author":"Hawser","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170623052554_CIT112C4","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623052554_CIT112C5","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170623052554_CIT112C6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijantimicag.2012.04.003","article-title":"High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia","volume":"40","author":"Wi","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170623052554_CIT112C10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"Yoon","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170623052554_CIT112C11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","article-title":"Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations","volume":"204","author":"Holmes","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1444-0903.2001.00029.x","article-title":"Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality","volume":"31","author":"Hill","year":"2001","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20170623052554_CIT112C14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00007691-199410000-00013","article-title":"Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight","volume":"16","author":"Ducharme","year":"1994","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20170623052554_CIT112C15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C16","author":"Cubicin package insert. Cubist Pharmaceuticals, Inc","year":"2010"},{"key":"key\n\t\t\t\t20170623052554_CIT112C17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/phar.1220","article-title":"Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"33","author":"Kullar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170623052554_CIT112C18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"Rehm","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170623052554_CIT112C20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjmed.2010.01.015","article-title":"The value of infectious diseases consultation in Staphylococcus aureus bacteremia","volume":"123","author":"Honda","year":"2010","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170623052554_CIT112C21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jinf.2009.07.015","article-title":"Mortality of S. aureus bacteremia and infectious diseases specialist consultation\u2014a study of 521 patients in Germany","volume":"59","author":"Rieg","year":"2009","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170623052554_CIT112C22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20170623052554_CIT112C23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/00365548.2012.669843","article-title":"Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin","volume":"44","author":"Marconescu","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623052554_CIT112C25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170623052554_CIT112C26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/j.1875-9114.2011.01017.x","article-title":"Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort","volume":"32","author":"Kullar","year":"2012","journal-title":"Pharmacotherapy"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/56\/11\/1562\/17850989\/cit112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T17:17:25Z","timestamp":1503422245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,2,28]]},"published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit112","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}